LENALIDOMIDE ZENTIVA 5 mg, hard capsule 21 capsules
Active ingredients: LÉNALIDOMIDE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule21 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LENALIDOMIDE ZENTIVA 5 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 21 gélule(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61310469CIP73020464CIP133400930204641Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉNALIDOMIDEgélule | 5 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: LENALIDOMIDE 5 mg - LENALIDOMIDE (CHLORHYDRATE DE) HYDRATE équivalant à LENALIDOMIDE 5 mg - REVLIMID 5 mg, gélule